Category - News

Developments

Kala Pharma reports positive results from Phase 3 dry eye disease trial

Kala Pharmaceuticals’ (NASDAQ:KALA) EYSUVIS met both primary efficacy endpoints in a Phase 3 trial for the short-term treatment of dry eye disease. The trial, called STRIDE 3, demonstrated a statistically significant...

March 9, 2020

Developments

Neuronetics gets FDA breakthrough device designation for NeuroStar

Neuronetics (NASDQ:STIM) received FDA breakthrough device designation for its NeuroStar Advanced Therapy System for the treatment of bipolar depression. Neurostar is a transcranial magnetic stimulation device that...

March 6, 2020

Developments

FDA clears Stereotaxis Genesis robotic magnetic navigation system

Stereotaxis (NYSE:STXS) received FDA 510(k) clearance of the Genesis RMN System for the robotic navigation of magnetic ablation catheters to treat heart rhythm disorders. “Genesis is a leap forward in robotic magnetic...

March 6, 2020

Markets

HCW slashes Eloxx Pharma PT to $3 from $10

H.C. Wainwright slashed its price target for Eloxx Pharmaceuticals (NASDAQ:ELOX) to $3 from $10 and retained its “neutral” rating, saying the strength of the company’s ELX-02 program in cystic fibrosis is yet to be...

March 6, 2020

Markets

SVB Leerink starts Osmotica Pharma at OP; PT $10

SVB Leerink launched coverage of Osmotica Pharmaceuticals (NASDAQ:OSMT) with an “outperform rating” and $10 price target. The stock closed at $5.47 on March 5. Analyst Ami Fadia writes that her rating is based on the...

March 6, 2020

Markets

Stifel starts Precision Biosciences at buy; PT $21

Stifel initiated coverage of Precision Biosciences (NASDAQ:DTIL) with a “buy” rating and $21 price target. The stock closed at $8.11 on March 4. “Our positive thesis is predicated on optimism that Precision’s allogeneic...

March 5, 2020

Executive Moves

Covetrus names Benjamin Wolin as CEO

Benjamin Wolin Benjamin Wolin, who has been acting CEO of Covetrus (NASDAQ:CVET) since October 2019, has been promoted to president and CEO, effective immediately. Covetrus was formed in February 2019 as the result of a...

March 4, 2020

Executive Moves

BioSig appoints John Osborn as consultant on autonomic neuromodulation

BioSig Technologies (NASDAQ:BSGM) signed a consulting agreement with John Osborn, Prof. in the Department of Surgery and director of the Minnesota Consortium for Autonomic Neuromodulation at University of Minnesota...

March 4, 2020

Developments

Omeros reports updated data from pivotal narsoplimab trial

Omeros (NASDAQ:OMER) reported updated data from its pivotal clinical trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. All 28 patients have completed...

March 3, 2020

Developments

Stealth gets FDA rare pediatric disease designation for elamipretide

Stealth BioTherapeutics’ (NASDAQ:MITO) elamipretide received FDA rare pediatric disease designation for the treatment of Barth syndrome. Barth syndrome is a very rare genetic condition characterized by cardiac...

March 3, 2020

Category - News

Kala Pharma reports positive results from Phase 3 dry eye disease trial

Neuronetics gets FDA breakthrough device designation for NeuroStar

FDA clears Stereotaxis Genesis robotic magnetic navigation system

HCW slashes Eloxx Pharma PT to $3 from $10

SVB Leerink starts Osmotica Pharma at OP; PT $10

Stifel starts Precision Biosciences at buy; PT $21

Covetrus names Benjamin Wolin as CEO

BioSig appoints John Osborn as consultant on autonomic neuromodulation

Omeros reports updated data from pivotal narsoplimab trial

Stealth gets FDA rare pediatric disease designation for elamipretide

General

More